Inotiv, Inc. (NOTV) Q4 2025 Earnings Call Transcript

Inotiv, Inc. (NOTV) Q2 2025 Earnings Call Transcript

Inotiv, Inc. (NOTV) Reports Q2 Loss, Tops Revenue Estimates

Inotiv (NOTV) delivered earnings and revenue surprises of 25% and 3.41%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Inotiv, Inc. (NOTV) May Report Negative Earnings: Know the Trend Ahead of Next Weeks Release

Inotiv (NOTV) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Inotiv, Inc. Announces Pricing of Public Offering of 6,000,000 Common Shares

WEST LAFAYETTE, Ind., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced the pricing of its underwritten public offering of 6,000,000 common shares at a price to the public of $4.25 per share. In addition, the Company has granted the underwriter a 30-day option to purchase u...

Inotiv, Inc. (NOTV) Q4 2024 Earnings Call Transcript

Inotiv, Inc. to Report Fiscal 2024 Fourth Quarter and Full Year Results and Host Conference Call on Tuesday, December 3, 2024

WEST LAFAYETTE, Ind., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 fourth quarter and full year ended September 30, 2024, on Tuesday, December 3, 2024, after the close of the stock market.

INOTIV ALERT: Bragar Eagel & Squire, P.C. is Investigating Inotiv, Inc. on Behalf of Inotiv Stockholders and Encourages Investors to Contact the Firm

NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Inotiv, Inc. (“Inotiv” or the “Company”) (NASDAQ: NOTV) on behalf of Inotiv stockholders. Our investigation concerns whether Inotiv has violated the federal securities laws and/or engaged in other unlawful business practices.

Inotiv, Inc. (NOTV) Q2 2024 Earnings Call Transcript

Inotiv, Inc. Reschedules its Fiscal 2024 Second Quarter Results

WEST LAFAYETTE, Ind., May 09, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the release of the Company’s financial results for the three and six months ended March 31, 2024 and the conference call to discuss the results that were originally scheduled for Friday, May 10, 202...